Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information
Depositor
Obinata, Masuo
Originator
Kobayashi, Syunsuke
Year of deposit
2005
Original cell
TKG0503
Animal
_human
< Mammals
Genus
Homo
Species
sapiens
Gender
Tissue
lung
Disease name
small cell carcinoma
Classification
cancer
History
Cell Resource Center for Biomedical Research, Tohoku University(TKG0503)
21514
Nomura M, Ohuchi M, Sakamoto Y, Kudo K, Yaku K, Soga T, Sugiura Y, Morita M, Hayashi K, Miyahara S, Sato T, Yamashita Y, Ito S, Kikuchi N, Sato I, Saito R, Yaegashi N, Fukuhara T, Yamada H, Shima H, Nakayama KI, Hirao A, Kawasaki K, Arai Y, Akamatsu S, Tanuma SI, Sato T, Nakagawa T, Tanuma N.
Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.Nat Commun
2023
14(1):8095
PubMed ID: 38092728
DOI: 10.1038/s41467-023-43630-3
9502
Morita M, Sato T, Nomura M, Sakamoto Y, Inoue Y, Tanaka R, Ito S, Kurosawa K, Yamaguchi K, Sugiura Y, Takizaki H, Yamashita Y, Katakura R, Sato I, Kawai M, Okada Y, Watanabe H, Kondoh G, Matsumoto S, Kishimoto A, Obata M, Matsumoto M, Fukuhara T, Motohashi H, Suematsu M, Komatsu M, Nakayama KI, Watanabe T, Soga T, Shima H, Maemondo M, Tanuma N.
PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth.Cancer Cell
2018
33:355-367.e7
PubMed ID: 29533781
DOI: 10.1016/j.ccell.2018.02.004
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x